Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only?
The BNT162b2 vaccine is reportedly effective in preventing severe disease in more than 90% of the general population, but its efficacy in transplant recipients remains controversial. We aimed to determine the immune response to the BNT162b2 vaccine in kidney (KTRs) and liver transplant recipients (L...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/12/1454 |
| _version_ | 1797500013942669312 |
|---|---|
| author | Paulina Nazaruk Marta Monticolo Anna Maria Jędrzejczak Natalia Krata Barbara Moszczuk Joanna Sańko-Resmer Tomasz Pilecki Arkadiusz Urbanowicz Michał Florczak Leszek Pączek Bartosz Foroncewicz Krzysztof Mucha |
| author_facet | Paulina Nazaruk Marta Monticolo Anna Maria Jędrzejczak Natalia Krata Barbara Moszczuk Joanna Sańko-Resmer Tomasz Pilecki Arkadiusz Urbanowicz Michał Florczak Leszek Pączek Bartosz Foroncewicz Krzysztof Mucha |
| author_sort | Paulina Nazaruk |
| collection | DOAJ |
| description | The BNT162b2 vaccine is reportedly effective in preventing severe disease in more than 90% of the general population, but its efficacy in transplant recipients remains controversial. We aimed to determine the immune response to the BNT162b2 vaccine in kidney (KTRs) and liver transplant recipients (LTRs). In this retrospective cohort study, we included randomly 65 KTRs and 65 LTRs, who received two 30 μg doses of BNT162b2 vaccine in 3-to6-week intervals. We analyzed the anti-SARS-CoV-2 spike protein IgG antibody (anti-S1 Ab) titer, biochemical liver and renal tests, immunosuppressive drug trough level, and clinical follow up 4–6 weeks after the first dose and 4–8 weeks after the second dose. The level of protective antibodies was 57.1% in KTRs and 88.9% in LTRs after the second dose. The anti-S1 Ab response was significantly associated with sex, age, and history of COVID-19. A tacrolimus dose at vaccination but not its trough level was significantly correlated with the increase in anti-S1 Ab titer after the second vaccine dose in LTRs. Rejection episodes did not occur after vaccination. Our results showed a higher than previously reported humoral response to the BNT162b2 vaccine in KTRs and LTRs, which was dependent upon age, type of transplanted organ, and immunosuppression. |
| first_indexed | 2024-03-10T03:55:44Z |
| format | Article |
| id | doaj.art-0ba01c9bf1db43f2b562df005581f3eb |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T03:55:44Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-0ba01c9bf1db43f2b562df005581f3eb2023-11-23T10:54:35ZengMDPI AGVaccines2076-393X2021-12-01912145410.3390/vaccines9121454Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only?Paulina Nazaruk0Marta Monticolo1Anna Maria Jędrzejczak2Natalia Krata3Barbara Moszczuk4Joanna Sańko-Resmer5Tomasz Pilecki6Arkadiusz Urbanowicz7Michał Florczak8Leszek Pączek9Bartosz Foroncewicz10Krzysztof Mucha11Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, PolandDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, PolandDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, PolandDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, PolandDepartment of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, PolandDepartment of Nephrology Nursing, Medical University of Warsaw, 02-007 Warsaw, PolandDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, PolandDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, PolandDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, PolandDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, PolandDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, PolandDepartment of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, PolandThe BNT162b2 vaccine is reportedly effective in preventing severe disease in more than 90% of the general population, but its efficacy in transplant recipients remains controversial. We aimed to determine the immune response to the BNT162b2 vaccine in kidney (KTRs) and liver transplant recipients (LTRs). In this retrospective cohort study, we included randomly 65 KTRs and 65 LTRs, who received two 30 μg doses of BNT162b2 vaccine in 3-to6-week intervals. We analyzed the anti-SARS-CoV-2 spike protein IgG antibody (anti-S1 Ab) titer, biochemical liver and renal tests, immunosuppressive drug trough level, and clinical follow up 4–6 weeks after the first dose and 4–8 weeks after the second dose. The level of protective antibodies was 57.1% in KTRs and 88.9% in LTRs after the second dose. The anti-S1 Ab response was significantly associated with sex, age, and history of COVID-19. A tacrolimus dose at vaccination but not its trough level was significantly correlated with the increase in anti-S1 Ab titer after the second vaccine dose in LTRs. Rejection episodes did not occur after vaccination. Our results showed a higher than previously reported humoral response to the BNT162b2 vaccine in KTRs and LTRs, which was dependent upon age, type of transplanted organ, and immunosuppression.https://www.mdpi.com/2076-393X/9/12/1454BNT162b2 mRNACOVID-19kidney transplantationliver transplantationSARS-CoV-2SOT |
| spellingShingle | Paulina Nazaruk Marta Monticolo Anna Maria Jędrzejczak Natalia Krata Barbara Moszczuk Joanna Sańko-Resmer Tomasz Pilecki Arkadiusz Urbanowicz Michał Florczak Leszek Pączek Bartosz Foroncewicz Krzysztof Mucha Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only? Vaccines BNT162b2 mRNA COVID-19 kidney transplantation liver transplantation SARS-CoV-2 SOT |
| title | Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only? |
| title_full | Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only? |
| title_fullStr | Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only? |
| title_full_unstemmed | Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only? |
| title_short | Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only? |
| title_sort | unexpectedly high efficacy of sars cov 2 bnt162b2 vaccine in liver versus kidney transplant recipients is it related to immunosuppression only |
| topic | BNT162b2 mRNA COVID-19 kidney transplantation liver transplantation SARS-CoV-2 SOT |
| url | https://www.mdpi.com/2076-393X/9/12/1454 |
| work_keys_str_mv | AT paulinanazaruk unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT martamonticolo unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT annamariajedrzejczak unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT nataliakrata unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT barbaramoszczuk unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT joannasankoresmer unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT tomaszpilecki unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT arkadiuszurbanowicz unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT michałflorczak unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT leszekpaczek unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT bartoszforoncewicz unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly AT krzysztofmucha unexpectedlyhighefficacyofsarscov2bnt162b2vaccineinliverversuskidneytransplantrecipientsisitrelatedtoimmunosuppressiononly |